comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 23:10:57 - browse：88

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Vivek Ramaswamy made waves in the debate, much as in biotech

hotspot

WSS

Intellia plays down concerns on accidental germline transmission

People can get long Covid without testing positive for virus: Study

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

National associations that represent hospice owe an apology

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

Poland's lawmakers approve a divisive law on Russian influence

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Apple is now the first public company to be valued at $3 trillion

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

United colonoscopy coverage change 'may cost lives,' doctors say

Europe is fastest

Medical leaders decry Supreme Court decision on affirmative action

How to make over

ChatGPT in medicine: STAT answers readers' burning questions

How the drug

Peter Hotez and the public health issue of online harassment

Vivek Ramaswamy made waves in the debate, much as in biotech

knowledge

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

Campaign finance charge dropped from case against Sam Bankman

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Study: Spinal cord stimulation helps patients with paralysis walk again

5 wounded, 2 critically, in Michigan shopping center shooting

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

leisure time

hotspot

explore

Wikipedia